Acadia Pharma (ACAD) Tops Q4 EPS by 3c
Tweet
Share
E-mail
Get Alerts ACAD Hot Sheet
Price: $22.50 +1.86%
EPS Growth %: -62.5%
Financial Fact:
Net loss per common share, basic and diluted: -0.61
Today's EPS Names:
MAYS, CRMT, REPL, More
EPS Growth %: -62.5%
Financial Fact:
Net loss per common share, basic and diluted: -0.61
Today's EPS Names:
MAYS, CRMT, REPL, More
Join SI Premium – FREE
Acadia Pharma (NASDAQ: ACAD) reported Q4 EPS of ($0.55), $0.03 better than the analyst estimate of ($0.58). Revenue for the quarter came in at $43.6 million versus the consensus estimate of $44.32 million.
For earnings history and earnings-related data on Acadia Pharma (ACAD) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Korn Ferry (KFY) Tops Q4 EPS by 2c, Beats on Revenue; Offers Q1 Guidance
- Bernstein SocGen Reiterates Outperform Rating on Fervo Energy (FRVO)
- Carnival shares drop despite earnings beat on weak guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
